:: Volume 12, Issue 6 (3-2011) ::
2011, 12(6): 569-579 Back to browse issues page
Comparison of Glucose Tolerance in Patients with Graves Disease Treated with Methimazole with Those who Have Received Radioiodine
Javad Kiani Dr., Vahid Yousefi Dr., Maryam Tohidi Dr., Yadollah Mehrabi Dr., Fereydun Azizi Dr.
Endocrine research institute , azizi@endocrine.ac.ir
Abstract:   (33563 Views)


Introduction: One of the major concern of the administration of radioiodine is its complications. Pancras has sodium iodine symporter and may concentrate radioiodine. This study compared glucose tolerance in Graves disease patients on continuous treatment with antithyroid drugs, with those who received radioiodine. Materials and Methods: In this study, 132 patients with Graves' disease who relapsed after drug  therapy  were randomly selected on by the patient preference for long-term treatment with either methimazole or radioactive iodine. In each group, fasting blood sugar, glucose tolerance test, and lipid profiles, TSH, insulin, HOMA-IR and HOMA-B were measured. Results: The two groups showed no significant difference in age sex, BMI and BP. Median FBS and HOMA-IR in the radioactive iodine group were higher than in the methimazole group (94 mg/dl vs. 90 mg/dl, P=0.019) and 1.5(1.2-2.3) vs. 1.3(0.8-2.1, P=0.045, respectively, but after adjustment there was no difference between the two groups no significant difference was seen in HOMA-B, median two-hour blood glucose and serum insulin levels, between the two groups. Conclusion: Results indicate no relationship between radioactive iodine treatment and glucose intolerance.

Keywords: Glucose tolerance, Graves disease, Radioactive iodineGlucose tolerance, Graves disease, Radioactive iodine
Full-Text [PDF 322 kb]   (2822 Downloads)    
Type of Study: Original | Subject: Endocrinology
Received: 2010/06/28

XML   Persian Abstract   Print

Volume 12, Issue 6 (3-2011) Back to browse issues page